ArticleBioinformatics (Oxford, England)2026
Interpretable deep survival analysis of Alzheimer's disease via metabolic genetic variants.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAlzheimer's disease (AD) is a progressive neurodegenerative disease. Traditional models for estimating AD onset cannot capture nonlinear interactions (epistasis) among the numerous genetic variables that contribute to AD risk.
methodsWe developed a feedforward neural network (FFN)-Weibull survival model to predict AD onset using large-scale single-nucleotide polymorphism (SNP) data. We integrated an XAI technique, Shapley additive explanations (SHAP), to address the black-box nature of deep learning, interpret model predictions, and quantify the contribution of each genetic factor to AD.
resultsThe FFN model achieved a mean concordance index of 0.647, demonstrating an approximately 3.6% improvement over the traditional linear baseline (0.625). The FFN-SHAP model validated established findings, identifying APOE E4 as a primary AD risk factor. APOE E2 strongly protected against AD. Metabolic-disorder-related SNPs had conflicting effects, suggesting gene-environment interactions influence AD onset.
conclusionsBy effectively bypassing the combinatorial explosion of interaction terms, the predictive power of an FFN combined with XAI provides a robust methodological tool for identifying the genetic basis of complex diseases, even in cohorts with limited sample sizes. Our model generated novel testable hypotheses regarding the intricate roles of gene-gene and gene-environment interactions in AD pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.